Table 3. Types of treatment in CHEK2 1100delC mutation carriers and noncarriers.

	Carrier		Noncarrier
	n	%	n	%	P-value
Surgical therapy
None	0	0	10	0.2	0.80
Lumpectomy	88	47.1	2087	46.4
Mastectomy	99	52.9	2405	53.4
Unknown	6		27
Adjuvant systemic therapy
None	117	63.2	2646	59.3	0.42
Only chemotherapy	32	17.3	826	18.5
Only hormonal therapy	12	6.5	441	9.9
Chemo- and hormonal therapy	24	13.0	547	12.3
Unknown	8		69
(Neo)-adjuvant chemotherapy
None	129	69.4	3089	69.0	0.41
Anthracyclines	38	20.4	838	18.7
Anthracyclines/taxanes	0	0	68	1.5
Other	16	8.6	435a	9.7
Unknown type	3	1.6	45	1.0
Unknown if treated	7		54
Adjuvant hormonal therapy
None	143	77.3	3392	76.0	0.46
LHRH/ other	6	3.2	84b	1.9
Tamoxifen	33	17.8	812	18.2
Aromatase inhibitor	1	0.5	29	0.6
Sequential tamoxifen/aromatase inhibitor	2	1.1	120	2.7
Unknown type	0	0	27	0.6
Unknown if treated	8		65
Radiotherapy
No	73	38.0	1298	28.7	0.006
Yes	119	62.0	3220	71.3
Unknown	1		11

Abbreviations: CHEK2=cell cycle checkpoint kinase 2; LHRH=luteinising-hormone-releasing hormone.

^aFour patients received taxanes.

^bFour patients were treated with radiotherapy of the ovaries or oophorectomy.